Cargando…
Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases
A unique case of multiple metastatic melanoma skin nodules regression in a heavily pretreated, 72-year-old Caucasian female, after administering the second dose of the SARS-CoV-2 mRNA Pfizer-BioNTech vaccine, is presented. Two days after vaccination, all her melanoma skin nodules became painful and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025412/ https://www.ncbi.nlm.nih.gov/pubmed/35455274 http://dx.doi.org/10.3390/vaccines10040525 |
_version_ | 1784690865285890048 |
---|---|
author | Bafaloukos, Dimitrios Petraki, Kalliopi Bousmpoukea, Aikaterini Chatzichristou, Eleni Pieris, Ioannis Koutserimpas, Christos Samonis, George |
author_facet | Bafaloukos, Dimitrios Petraki, Kalliopi Bousmpoukea, Aikaterini Chatzichristou, Eleni Pieris, Ioannis Koutserimpas, Christos Samonis, George |
author_sort | Bafaloukos, Dimitrios |
collection | PubMed |
description | A unique case of multiple metastatic melanoma skin nodules regression in a heavily pretreated, 72-year-old Caucasian female, after administering the second dose of the SARS-CoV-2 mRNA Pfizer-BioNTech vaccine, is presented. Two days after vaccination, all her melanoma skin nodules became painful and were significantly reduced in size. Physical examination and ultrasound imaging confirmed the patient’s observation. The effect was sustained, and further reduction of the nodules occurred after the third vaccine dose. One of the reduced nodules was removed, histologically examined, and its histopathology was compared to that of another such nodule removed and examined earlier. Distinct differences were observed between the two histopathologies, with the most notable the unexpected finding of the absence of infiltrating lymphocytes in the reducer nodule’s melanoma tissue. Based on this observation, the possible immunological mechanism(s) leading to the vaccine’s effect are speculated. More possible is the vaccine’s antitumor and apoptotic activity via stimulation of the Tol Like Receptors 3, 7, and 8, and (downstream) the nuclear factor kappa-light-chain-enhancer of the activated B cells pathway of the non-lymphocytic immune effector cells. |
format | Online Article Text |
id | pubmed-9025412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90254122022-04-23 Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases Bafaloukos, Dimitrios Petraki, Kalliopi Bousmpoukea, Aikaterini Chatzichristou, Eleni Pieris, Ioannis Koutserimpas, Christos Samonis, George Vaccines (Basel) Case Report A unique case of multiple metastatic melanoma skin nodules regression in a heavily pretreated, 72-year-old Caucasian female, after administering the second dose of the SARS-CoV-2 mRNA Pfizer-BioNTech vaccine, is presented. Two days after vaccination, all her melanoma skin nodules became painful and were significantly reduced in size. Physical examination and ultrasound imaging confirmed the patient’s observation. The effect was sustained, and further reduction of the nodules occurred after the third vaccine dose. One of the reduced nodules was removed, histologically examined, and its histopathology was compared to that of another such nodule removed and examined earlier. Distinct differences were observed between the two histopathologies, with the most notable the unexpected finding of the absence of infiltrating lymphocytes in the reducer nodule’s melanoma tissue. Based on this observation, the possible immunological mechanism(s) leading to the vaccine’s effect are speculated. More possible is the vaccine’s antitumor and apoptotic activity via stimulation of the Tol Like Receptors 3, 7, and 8, and (downstream) the nuclear factor kappa-light-chain-enhancer of the activated B cells pathway of the non-lymphocytic immune effector cells. MDPI 2022-03-28 /pmc/articles/PMC9025412/ /pubmed/35455274 http://dx.doi.org/10.3390/vaccines10040525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Bafaloukos, Dimitrios Petraki, Kalliopi Bousmpoukea, Aikaterini Chatzichristou, Eleni Pieris, Ioannis Koutserimpas, Christos Samonis, George Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title | Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title_full | Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title_fullStr | Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title_full_unstemmed | Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title_short | Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases |
title_sort | therapeutic effect of mrna sars-cov-2 vaccine on melanoma skin metastases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025412/ https://www.ncbi.nlm.nih.gov/pubmed/35455274 http://dx.doi.org/10.3390/vaccines10040525 |
work_keys_str_mv | AT bafaloukosdimitrios therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT petrakikalliopi therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT bousmpoukeaaikaterini therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT chatzichristoueleni therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT pierisioannis therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT koutserimpaschristos therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases AT samonisgeorge therapeuticeffectofmrnasarscov2vaccineonmelanomaskinmetastases |